Fig. 1.

Representative examples of performed immunological analyses. a ELISPOT assays performed after 180 days from vaccination on PBMC from patient #16 (low response, upper panels) and after 90 days from vaccination on PBMC from patient #67 (high response, lower panels); b intracellular cytokine staining of CD8-IFNγ + and CD8 + IFNγ + circulating T cells specific for GX301 peptides after 180 days from vaccination in blood sample derived from patient #51 (low response, upper panels) and after 90 days from vaccination in blood sample derived from patient #32 (high response, lower panels); c GX301 peptides specific cytotoxicity assays performed after 90 days from the first immunization with PBMC of patient #35 (low response, upper panels) and patient #72 (high response, lower panels) against autologous monocytes pulsed (right panels) or not (left panels) with the four GX301 peptides